心臟手術中的分子氫治療：改善紅血球功能和降低氧化壓力的臨床證據

The study you mentioned investigates the effects of molecular hydrogen (H₂) on red blood cells (RBCs) and cardiac function in patients undergoing surgery with cardiopulmonary bypass (CPB) for valve defects. Here’s a summary of the findings:

Study Design and Methods:

Participants: 24 patients undergoing elective surgery with CPB, randomly assigned to two groups.
- Research Group (12 patients): Received H₂ at a concentration of 1.5-2.0% via a facemask throughout the operation.
- Control Group (12 patients): Did not receive H₂.
Sample Collection: Blood samples were taken at four stages:
1. After anesthesia introduction.
2. Before CPB.
3. After CPB termination.
4. 24 hours post-operation.

Results:

Red Blood Cell Function:
- Electrophoretic Mobility: Increased in the H₂ group, indicating enhanced RBC function.
- Metabolism: Enhanced in the H₂ group.
- Aggregation: Decreased in the H₂ group, suggesting improved RBC fluidity.
Oxidative Stress:
- Reduction: Significant decrease in oxidative stress markers in the H₂ group, particularly noticeable 24 hours post-operation.
Cardiac Function:
- Myocardial Contractile Function: Improved in the H₂ group on the 1st and 3rd days post-surgery compared to the control group.

Conclusion:

The inhalation of molecular hydrogen appears to improve the functional state of red blood cells and reduce oxidative stress, contributing to a better early postoperative course. This suggests that H₂ has protective properties, potentially enhancing recovery after surgery with CPB.

The study supports the idea that molecular hydrogen could be a beneficial adjunct in surgical settings, particularly in managing oxidative stress and RBC functionality.